Masahiro Hatori

6PUBLICATIONS
18CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 19, 2026
Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer.

|Aug 28, 2026
Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study.

|Jun 01, 2026
Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study.

|Apr 29, 2024
Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).

Masahiro Hatori, Daiki Tsuji, Kenichi Suzuki

|Sep 07, 2023
Influence of menopause on chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study.

Takashi Yokokawa, Kenichi Suzuki, Daiki Tsuji

|Oct 22, 2021
Association Between Regorafenib Dose and Efficacy Against Metastatic Colorectal Cancer in a Real-World Setting.

Masahiro Hatori, Kazuyoshi Kawakami, Takeru Wakatsuki

Pageof 1

Frequent Collaborators

5 joint publications

Kazuyoshi Kawakami

5 joint publications

Takashi Yokokawa

5 joint publications

Daiki Tsuji

4 joint publications

Kunihiko Itoh